Dr. Andreas Seidl is Chairman of Leukocare’s Scientific Advisory Board and coordinates the activities of the members of the SAB to support Leukocare´s innovation processes in bioinformatics, analytics, and drug product development. Andreas is CSO of Formycon, leading the preclinical and clinical development, bioanalytics and Scientific Affairs functions. He has over 20 years experience in analytical and pharmaceutical development of biologics and contributed to the development and approval of many biosimilar products and NBEs. He has held different positions with growing responsibility at Hexal AG, Sandoz Biopharmaceuticals and Novartis. Andreas is a chemist by training with a master’s degree from the University of Constance/Germany and received his Ph.D. in the area of protein analysis and mass spectrometry from the University of Constance.

Prof. Johannes Buchner received his PhD from the University of Regensburg, Germany. After a postdoctoral stay at the National Cancer Institute of the NIH in Bethesda, USA, he was a group leader at the University of Regensburg. Since 1998 he is a professor for Biotechnology at the Technical University of Munich/ Germany. He is a member of the Leopoldina, the German National Academy of Sciences. His research interests include mechanistic studies on molecular chaperones, principles of antibody/protein folding and association, as well as their evolution. Johannes Buchner received several prizes for his work, including the Hans Neurath Award, the Kossel-Award, the Max Bergmann Medal and the Schleiden Medal. He has authored 275 publications in peer-reviewed journals.

Prof. Paul Dalby is Director of the EPSRC Centre for Doctoral Training in Emergent Macromolecular Therapies, Co-Director of the EPSRC Future Targeted Healthcare Manufacturing Hub, and Deputy Head of the Department of Biochemical Engineering at University College London. He also Chairs the Biotechnology Group of the Royal Society of Chemistry. His research focuses on routes to improve therapeutic proteins for ease of manufacture, formulation and delivery to patients. He combines protein engineering and formulation, with biophysical characterisation, molecular modelling and simulation, to understand the factors that influence protein stability, and to guide protein engineering and formulation for improved properties. He has authored over 90 numerous publications in peer-reviewed journals. Prof. Ulrike Protzer Prof. Ulrike Protzer More information

Prof. Ulrike Protzer studied medicine in Germany, South Africa and Switzerland. She is an expert clinical virologist with clinical training in infectious diseases and hepatology before she focused on virology. Her scientific efforts focus on understanding the interaction between viruses and their hosts and on translating this knowledge into novel therapies and vaccines. Since 2007, she is a professor for Virology at the Technical University of Munich and at Helmholtz Zentrum Muenchen. She is leading three national and international research consortia, was member of the executive board of the German Center for Infection Research and now is the speaker of its Thematic Translational Unit “Viral Hepatitis”. She has published more than 145 peer-reviewed papers and 30 review articles and holds several international patents.

Prof. Theodore W. Randolph has more than 30 years of experience in Pharmaceutical Biotechnology . He is professor and Co-Director at the Center for Pharmaceutical Biotechnology, University of Colorado/Boulder. His research interests include stabilization and formulation of Therapeutic Proteins- “Converting Molecules into Drugs”, application of biophysical methods for formulation development, aggregation & immunogenicity of protein therapeutics, and stability of protein-based vaccines. He has published more than 230 scientific articles in peer-reviewed journals, has been rewarded 14 research awards and is editorial board member of several scientific journals.

Bernhardt L. Trout is the Raymond F. Baddour, ScD, (1949) Professor of Chemical Engineering at MIT. He received his S.B. and S.M. degrees from MIT and his Ph.D. from the University of California at Berkeley. In addition, he performed post-doctoral research at the Max-Planck Institute. Trout’s research focuses on the development of advanced manufacturing processes and rational tools for formulation and product design, primarily liquid formulations, but also lyophilized formulations. A major aspect of his work relates to the development of both microscopic and macroscopic models to design stable formulations efficiently. Together with colleagues from MIT, he set-up the Novartis-MIT Center for Continuous Manufacturing in 2007 which until 2019 actively pursued the objective of transforming pharmaceutical production. He has published over 200 papers and has 18 patents issued or pending. For more information on Prof. Trout and his research, please visit: http://web.mit.edu/troutgroup/